NEW YORK (GenomeWeb News) — Metabolon said yesterday that the US Army Medical Research Institute of Infectious Diseases will use its metabolomics platform to study the effects of the AVA anthrax vaccine in humans.
Metabolon's chief science officer Mike Milburn said the collaboration on the FDA-approved vaccine is the “first large-scale metabolomics study of human subjects given a vaccine.”
"This type of comprehensive biochemical profiling will help USAMRIID better understand the vaccine's safety, efficacy, and mechanism of action," Milburn added.
Metabolon’s technology performs in drug studies by measuring the spectrum of biochemical changes and maps them to metabolic pathways, the company said.
Financial terms of the agreement were not released.